Reflections on new developments in the KRAS niche
In our the third of our AACR 2020 Preview series, we turn to the KRAS pathway to look at some new aspects, whether they be new targets, novel agents in development or even twists on the biology of the disease.
There’s quite a bit to discuss here, certainly more than I was expecting considering it was expected to be a down year by some after all the excitement of last year’s revelations and developments in the clinic!
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the annual AACR meeting subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers